1. Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med. 2020;26:1256–63.
2. Wang P, Wang F, Ni L, Wu P, Chen J. Targeting redox-altered plasticity to reactivate synaptic function: A novel therapeutic strategy for cognitive disorder. Acta Pharm Sin B. 2021;11:599–608.
3. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.
4. Jiang X, Lu H, Li J, Liu W, Wu Q, Xu Z, et al. A natural BACE1 and GSK3beta dual inhibitor Notopterol effectively ameliorates the cognitive deficits in APP/PS1 Alzheimer’s mice by attenuating amyloid-beta and tau pathology. Clin Transl Med. 2020;10:e50.
5. Zhang F, Gannon M, Chen Y, Yan S, Zhang S, Feng W, et al. Beta-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3beta/tau cascade. Sci Transl Med. 2020;16:e044769.